Tirdzniecība Durect - DRRX CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Starpība | 0.0552 | ||||||||
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.030779% | ||||||||
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | -0.013666% | ||||||||
Nakts laika nodeva | 22:00 (UTC) | ||||||||
Min. tirgotais daudzums | 0.01 | ||||||||
Valūta | USD | ||||||||
Drošības rezerve | 20% | ||||||||
Fondu birža | United States of America | ||||||||
Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Iepriekš. aizvērt* | 6.0814 |
Atvērt* | 5.842 |
Izmaiņas par 1 gadu* | 734.57% |
Dienas Diapazons* | 5.6128 - 6.0216 |
52 ned Diapazons | 0.36-1.13 |
Vidējais apjoms (10 dienas) | 174.55K |
Vidējais apjoms (3 mēneši) | 4.67M |
Tirgus Kapitalizācija | 109.37M |
Cenas/Peļņas Attiecība | -100.00K |
Izvietotās Akcijas | 227.86M |
Ieņēmumi | 23.27M |
EPS | -0.14 |
Dividende (Ienesīgums %) | N/A |
Beta | 1.23 |
Nākamās Peļņas Datums | Mar 6, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
---|---|---|---|---|---|---|
Feb 8, 2023 | 5.7924 | -0.0994 | -1.69% | 5.8918 | 6.0216 | 5.5829 |
Feb 7, 2023 | 6.0814 | 0.3988 | 7.02% | 5.6826 | 6.2909 | 5.5328 |
Feb 6, 2023 | 5.6926 | -0.0398 | -0.69% | 5.7324 | 6.1713 | 5.5828 |
Feb 3, 2023 | 6.3705 | 0.1793 | 2.90% | 6.1912 | 6.4404 | 6.1210 |
Feb 2, 2023 | 6.3606 | 0.2595 | 4.25% | 6.1011 | 6.4305 | 5.8519 |
Feb 1, 2023 | 6.2011 | -0.2692 | -4.16% | 6.4703 | 6.5301 | 6.0912 |
Jan 31, 2023 | 6.4403 | 0.0700 | 1.10% | 6.3703 | 6.5301 | 6.3703 |
Jan 30, 2023 | 6.3904 | 0.0300 | 0.47% | 6.3604 | 6.4704 | 6.3604 |
Jan 27, 2023 | 6.4603 | 0.1200 | 1.89% | 6.3403 | 6.6996 | 6.2406 |
Jan 26, 2023 | 6.3705 | -0.0595 | -0.93% | 6.4300 | 6.5301 | 6.3307 |
Jan 25, 2023 | 6.4902 | -0.0395 | -0.60% | 6.5297 | 6.7993 | 6.3104 |
Jan 24, 2023 | 6.6895 | 0.4389 | 7.02% | 6.2506 | 6.9888 | 6.0114 |
Jan 23, 2023 | 6.3105 | 0.0297 | 0.47% | 6.2808 | 6.6099 | 5.8619 |
Jan 20, 2023 | 6.3108 | 0.1300 | 2.10% | 6.1808 | 6.6697 | 5.7721 |
Jan 19, 2023 | 6.2111 | -0.4283 | -6.45% | 6.6394 | 7.1979 | 6.1309 |
Jan 18, 2023 | 6.7595 | -2.2429 | -24.91% | 9.0024 | 9.4115 | 6.2806 |
Jan 17, 2023 | 8.6337 | 1.1566 | 15.47% | 7.4771 | 8.9629 | 7.4771 |
Jan 13, 2023 | 7.4573 | 0.5783 | 8.41% | 6.8790 | 7.5867 | 6.8788 |
Jan 12, 2023 | 6.7993 | -0.0299 | -0.44% | 6.8292 | 6.8791 | 6.5397 |
Jan 11, 2023 | 6.8790 | 0.0499 | 0.73% | 6.8291 | 6.9290 | 6.4799 |
Durect Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Ikgadējs
- Ceturkšņa
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Kopējie ienākumi | 14.025 | 49.17 | 15.275 | 25.074 | 30.111 | 13.977 |
Ienākumi | 14.025 | 49.17 | 15.275 | 25.074 | 30.111 | 13.977 |
Cost of Revenue, Total | 5.29 | 6.633 | 1.64 | 1.263 | 1.406 | 1.955 |
Bruto Peļņa | 8.735 | 42.537 | 13.635 | 23.811 | 28.705 | 12.022 |
Kopējie Darbības Izdevumi | 46.389 | 51.407 | 38.915 | 45.018 | 42.726 | 48.25 |
Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 11.825 | 13.165 | 12.262 | 14.115 | 13.611 | 14.449 |
Pētniecība un Attīstība | 29.274 | 31.609 | 25.013 | 29.64 | 27.709 | 31.846 |
Darbības Izdevumi | -32.364 | -2.237 | -23.64 | -19.944 | -12.615 | -34.273 |
Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -2.145 | -1.458 | -1.703 | -1.427 | -1.72 | -1.992 |
Neto Ienākumi Pirms Nodokļu Nomaksas | -34.509 | -3.695 | -25.343 | -21.371 | -14.335 | -36.265 |
Neto Ienākumi Pēc Nodokļu Nomaksas | -34.509 | -3.695 | -25.343 | -21.371 | -14.335 | -36.265 |
Neto Ienākumi Pirms Ārkārtas Posteņiem | -34.509 | -3.695 | -25.343 | -21.371 | -14.335 | -36.265 |
Neto Ienākumi | -34.509 | -3.695 | -25.322 | -20.578 | -0.582 | -36.265 |
Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -34.509 | -3.695 | -25.343 | -21.371 | -14.335 | -36.265 |
Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -34.509 | -3.695 | -25.322 | -20.578 | -0.582 | -36.265 |
Atšķaidītie Neto Ienākumi | -34.509 | -3.695 | -25.322 | -20.578 | -0.582 | -36.265 |
Atšķaidītie Ienākumi par Akcijām | 133.163 | 145.273 | 159.834 | 178.042 | 199.457 | 225.047 |
Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -0.25915 | -0.02543 | -0.15856 | -0.12003 | -0.07187 | -0.16114 |
Atšķaidītā Normalizētā Peļņa par Akciju | -0.25915 | -0.02543 | -0.15856 | -0.12003 | -0.07187 | -0.16114 |
Ārkārtas Posteņi Kopā | 0 | 0.021 | 0.793 | 13.753 | 0 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Kopējie ienākumi | 2.212 | 2.303 | 2.165 | 7.297 | 1.915 |
Ienākumi | 2.212 | 2.303 | 2.165 | 7.297 | 1.915 |
Cost of Revenue, Total | 0.352 | 0.359 | 0.364 | 0.88 | 0.335 |
Bruto Peļņa | 1.86 | 1.944 | 1.801 | 6.417 | 1.58 |
Kopējie Darbības Izdevumi | 11.858 | 10.96 | 11.623 | 13.809 | 12.281 |
Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 3.531 | 3.168 | 3.236 | 4.514 | 3.735 |
Pētniecība un Attīstība | 7.975 | 7.433 | 8.023 | 8.415 | 8.211 |
Darbības Izdevumi | -9.646 | -8.657 | -9.458 | -6.512 | -10.366 |
Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -0.488 | -0.489 | -0.519 | -0.496 | -0.476 |
Neto Ienākumi Pirms Nodokļu Nomaksas | -10.134 | -9.146 | -9.977 | -7.008 | -10.842 |
Neto Ienākumi Pēc Nodokļu Nomaksas | -10.134 | -9.146 | -9.977 | -7.008 | -10.842 |
Neto Ienākumi Pirms Ārkārtas Posteņiem | -10.134 | -9.146 | -9.977 | -7.008 | -10.842 |
Ārkārtas Posteņi Kopā | 0 | 0 | 0 | 0 | |
Neto Ienākumi | -10.134 | -9.146 | -9.977 | -7.008 | -10.842 |
Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -10.134 | -9.146 | -9.977 | -7.008 | -10.842 |
Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -10.134 | -9.146 | -9.977 | -7.008 | -10.842 |
Atšķaidītie Neto Ienākumi | -10.134 | -9.146 | -9.977 | -7.008 | -10.842 |
Atšķaidītie Ienākumi par Akcijām | 217.537 | 227.428 | 227.499 | 227.615 | 227.688 |
Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -0.04659 | -0.04021 | -0.04386 | -0.03079 | -0.04762 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Atšķaidītā Normalizētā Peļņa par Akciju | -0.04659 | -0.04021 | -0.04386 | -0.03079 | -0.04762 |
- Ikgadējs
- Ceturkšņa
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Apgrozāmo Līdzekļu Kopsumma | 32.426 | 45.358 | 41.74 | 71.829 | 63.061 | 81.737 |
Nauda un Īstermiņa Ieguldījumi | 25.004 | 36.759 | 34.315 | 64.674 | 40.733 | 69.81 |
Nauda un Ekvivalenti | 5.404 | 29.375 | 31.644 | 34.924 | 21.312 | 49.844 |
Īstermiņa Ieguldījumi | 19.6 | 7.384 | 2.671 | 29.75 | 19.421 | 19.966 |
Debitoru Parādu Kopsumma, Neto | 1.154 | 2.376 | 1.757 | 2.313 | 0.94 | 6.477 |
Accounts Receivable - Trade, Net | 1.154 | 2.376 | 1.757 | 2.313 | 0.94 | 6.477 |
Total Inventory | 3.782 | 3.163 | 3.421 | 3.383 | 1.864 | 1.87 |
Prepaid Expenses | 2.486 | 3.06 | 2.247 | 1.459 | 4.545 | 3.58 |
Total Assets | 40.508 | 53.113 | 49.999 | 86.02 | 75.641 | 91.99 |
Property/Plant/Equipment, Total - Net | 1.297 | 0.929 | 0.605 | 6.535 | 5 | 3.673 |
Property/Plant/Equipment, Total - Gross | 22.673 | 22.736 | 22.646 | 28.867 | 24.109 | 22.616 |
Accumulated Depreciation, Total | -21.376 | -21.807 | -22.041 | -22.332 | -19.109 | -18.943 |
Goodwill, Net | 6.399 | 6.399 | 6.399 | 6.399 | 6.169 | 6.169 |
Other Long Term Assets, Total | 0.386 | 0.427 | 1.255 | 1.257 | 0.411 | 0.411 |
Total Current Liabilities | 28.75 | 15.828 | 7.662 | 36.768 | 10.703 | 10.056 |
Accounts Payable | 2.086 | 1.52 | 1.589 | 2.109 | 1.678 | 1.311 |
Accrued Expenses | 5.06 | 5.511 | 4.668 | 8.327 | 7.596 | 8.55 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 19.853 | 7.281 | 0 | 0.884 | 0 | |
Other Current Liabilities, Total | 1.751 | 1.516 | 1.405 | 26.332 | 0.545 | 0.195 |
Total Liabilities | 32.17 | 31.625 | 29.999 | 63.16 | 35.526 | 34.208 |
Total Long Term Debt | 0 | 12.634 | 20.533 | 20.262 | 19.936 | 20.632 |
Long Term Debt | 0 | 12.634 | 20.533 | 20.262 | 19.936 | 20.632 |
Other Liabilities, Total | 3.42 | 3.163 | 1.804 | 6.13 | 4.887 | 3.52 |
Total Equity | 8.338 | 21.488 | 20 | 22.86 | 40.115 | 57.782 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 | |
Common Stock | 0.014 | 0.015 | 0.016 | 0.019 | 0.02 | 0.023 |
Additional Paid-In Capital | 448.404 | 465.246 | 488.608 | 512.046 | 529.884 | 583.818 |
Retained Earnings (Accumulated Deficit) | -440.077 | -443.772 | -468.624 | -489.202 | -489.784 | -526.049 |
Other Equity, Total | -0.003 | -0.001 | 0 | -0.003 | -0.005 | -0.01 |
Total Liabilities & Shareholders’ Equity | 40.508 | 53.113 | 49.999 | 86.02 | 75.641 | 91.99 |
Total Common Shares Outstanding | 141.297 | 150.837 | 162.06 | 195.257 | 203.533 | 227.68 |
Other Current Assets, Total | 14.979 | 0 | ||||
Long Term Investments | 1 | 0 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Apgrozāmo Līdzekļu Kopsumma | 104.811 | 95.356 | 87.25 | 81.737 | 70.635 |
Nauda un Īstermiņa Ieguldījumi | 97.083 | 88.43 | 80.796 | 69.81 | 64.201 |
Nauda un Ekvivalenti | 57.545 | 56.073 | 55.412 | 49.844 | 49.44 |
Īstermiņa Ieguldījumi | 39.538 | 32.357 | 25.384 | 19.966 | 14.761 |
Debitoru Parādu Kopsumma, Neto | 0.993 | 0.816 | 0.946 | 6.477 | 0.96 |
Accounts Receivable - Trade, Net | 0.993 | 0.816 | 0.946 | 6.477 | 0.96 |
Total Inventory | 1.955 | 1.918 | 2.27 | 1.87 | 2.076 |
Prepaid Expenses | 4.78 | 4.192 | 3.238 | 3.58 | 3.398 |
Other Current Assets, Total | 0 | 0 | 0 | ||
Total Assets | 116.055 | 106.267 | 97.962 | 91.99 | 80.531 |
Property/Plant/Equipment, Total - Net | 4.664 | 4.331 | 4.132 | 3.673 | 3.316 |
Goodwill, Net | 6.169 | 6.169 | 6.169 | 6.169 | 6.169 |
Long Term Investments | 0 | 0 | 0 | 0 | |
Other Long Term Assets, Total | 0.411 | 0.411 | 0.411 | 0.411 | 0.411 |
Total Current Liabilities | 11.704 | 8.218 | 9.565 | 10.056 | 9.023 |
Accounts Payable | 2.15 | 1.086 | 1.894 | 1.311 | 2.269 |
Accrued Expenses | 5.902 | 6.935 | 7.576 | 8.55 | 6.357 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 2.895 | 0 | 0 | 0 | |
Other Current Liabilities, Total | 0.757 | 0.197 | 0.095 | 0.195 | 0.397 |
Total Liabilities | 34.332 | 32.804 | 33.935 | 34.208 | 32.924 |
Total Long Term Debt | 18.062 | 20.36 | 20.496 | 20.632 | 20.765 |
Long Term Debt | 18.062 | 20.36 | 20.496 | 20.632 | 20.765 |
Other Liabilities, Total | 4.566 | 4.226 | 3.874 | 3.52 | 3.136 |
Total Equity | 81.723 | 73.463 | 64.027 | 57.782 | 47.607 |
Common Stock | 0.023 | 0.023 | 0.023 | 0.023 | 0.023 |
Additional Paid-In Capital | 581.632 | 582.505 | 583.043 | 583.818 | 584.504 |
Retained Earnings (Accumulated Deficit) | -499.918 | -509.064 | -519.041 | -526.049 | -536.891 |
Other Equity, Total | -0.014 | -0.001 | 0.002 | -0.01 | -0.029 |
Total Liabilities & Shareholders’ Equity | 116.055 | 106.267 | 97.962 | 91.99 | 80.531 |
Total Common Shares Outstanding | 227.406 | 227.496 | 227.506 | 227.68 | 227.694 |
Property/Plant/Equipment, Total - Gross | 22.616 | ||||
Accumulated Depreciation, Total | -18.943 | ||||
Preferred Stock - Non Redeemable, Net | 0 |
- Ikgadējs
- Ceturkšņa
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Neto ienākumi/Sākuma Līnija | -34.509 | -3.695 | -25.322 | -20.578 | -0.582 | -36.265 |
Nauda no Darbības | -27.293 | -1.343 | -19.75 | 11.101 | -38.704 | -37.311 |
Nauda no Darbības | 0.416 | 0.437 | 0.254 | 0.291 | 0.297 | 0.288 |
Bezskaidras Naudas Preces | 3.239 | 4.385 | 3.522 | 3.034 | -10.402 | 3.03 |
Samaksātie Procenti Naudā | 1.611 | 1.703 | 1.886 | 1.942 | 1.678 | 1.617 |
Izmaiņas Apgrozāmajā Kapitālā | 3.561 | -2.47 | 1.796 | 28.354 | -28.017 | -4.364 |
Nauda no Ieguldījumu Darbībām | 6.037 | 12.69 | 4.537 | -27.324 | 9.432 | 15.311 |
Kapitālie Izdevumi | -0.147 | -0.069 | -0.093 | -0.155 | -0.208 | -0.194 |
Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | 6.184 | 12.759 | 4.63 | -27.169 | 9.64 | 15.505 |
Nauda no Darbībām ar Finansēšanu | 23.077 | 12.624 | 17.482 | 19.503 | 15.66 | 50.532 |
Naudas Plūsma Finansēšanas Posteņos | -0.173 | 0 | ||||
Akciju Izsniegšana (Atkāpšanās), Neto | 24.155 | 12.638 | 18.505 | 20.339 | 15.664 | 51.247 |
Parādu Izsniegšana (Atkāpšanās), Neto | -0.905 | -0.014 | -1.023 | -0.836 | -0.004 | -0.715 |
Neto Izmaiņas Naudā | 1.821 | 23.971 | 2.269 | 3.28 | -13.612 | 28.532 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -10.134 | -19.28 | -29.257 | -36.265 | -10.842 |
Cash From Operating Activities | -10.709 | -18.841 | -26.2 | -37.311 | -5.559 |
Cash From Operating Activities | 0.03 | 0.06 | 0.092 | 0.288 | 0.034 |
Non-Cash Items | 0.77 | 1.539 | 2.303 | 3.03 | 0.791 |
Changes in Working Capital | -1.375 | -1.16 | 0.662 | -4.364 | 4.458 |
Cash From Investing Activities | -4.106 | 3.104 | 9.919 | 15.311 | 5.147 |
Capital Expenditures | -0.003 | -0.02 | -0.184 | -0.194 | -0.033 |
Other Investing Cash Flow Items, Total | -4.103 | 3.124 | 10.103 | 15.505 | 5.18 |
Cash From Financing Activities | 51.048 | 50.498 | 50.381 | 50.532 | 0.008 |
Issuance (Retirement) of Stock, Net | 51.049 | 51.212 | 51.096 | 51.247 | 0.008 |
Issuance (Retirement) of Debt, Net | -0.001 | -0.714 | -0.715 | -0.715 | 0 |
Net Change in Cash | 36.233 | 34.761 | 34.1 | 28.532 | -0.404 |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com GroupTirgotāji
Ikmēneša aktīvie klienti
Ikmēneša ieguldījumu apjoms
Izņemts katru mēnesi
Treidinga kalkulators
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Durect Company profile
Par Durect
DURECT Corporation ir biofarmācijas uzņēmums, kas koncentrējas uz dzīvību glābjošu pētniecisko terapiju attīstīšanu. Uzņēmuma kandidātprodukti ir DUR-928, ko lieto iekšķīgi, lai ārstētu vielmaiņas/lipīdu sistēmas traucējumus, un DUR-928, ko injicē, lai ārstētu akūtas orgānu traumas. Uzņēmuma citi komerciālie kandidātprodukti ir POSIMIR, PERSERIS un Methydur ilgstošās atbrīvošanas kapsulas. Uzņēmums veic larsukosterīna (DUR-928) IIb fāzes pētījumu (AHFIRM) personām ar smagu alkohola izraisītu hepatītu (Alkoholiskais hepatīts (AH), lai novērtētu larsukosterīna terapijas drošību un efektivitāti. Larsukosterols (DUR-928) ir galvenais kandidātprodukts, endogēns sulfātoksisterols un epigenētiskais regulators. Uzņēmums koncentrējas uz zāļu piegādes tehnoloģijām, izmantojot SABER un CLOUD Bioerodible Injectable Depot sistēmas. SABER izmanto augstas viskozitātes bāzes komponentu, piemēram, saharozes acetāta izobutirātu (SAIB), lai nodrošinātu kontrolētu zāļu izdalīšanos.
Industry: | Bio Therapeutic Drugs |
10260 Bubb Rd
95014
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 500 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com